Treatment Advances in Wet Age-Related Macular Degeneration

Thomas A. Ciulla, MD, MBA


March 31, 2023

Age-related macular degeneration (AMD) is among the leading causes of irreversible blindness worldwide. Of the two types, wet AMD is less common and more severe. Nevertheless, approximately 200,000 people in the United States are newly diagnosed with wet AMD each year.

Anti-VEGF therapy has become the standard of care and may help slow disease progression and preserve vision. Current injectable therapies approved by the FDA for wet AMD include ranibizumab, aflibercept, and brolucizumab. In addition, bevacizumab is used off-label for treatment of wet AMD.

Exploration of new delivery options and longer duration of therapy has been underway for several years in the field of AMD; faricimab, a combined-mechanism medication, was approved in 2022 and targets two distinct pathways: VEGF-A and Ang-2.

Dr Thomas Ciulla, of the Indiana University School of Medicine, discusses the current armamentarium as well as new agents undergoing clinical trials.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.